Phosphoprotein Phosphatase 2A: A Novel Druggable Target for Alzheimer’s Disease
Citations Over TimeTop 10% of 2011 papers
Abstract
Tau hyperphosphorylation is thought to play an important role in the etiology of Alzheimer's disease by facilitating the formation of neurofibrillary tangles. Reducing phosphorylation through kinase inhibition has therefore emerged as a target for drug development, but despite considerable efforts to develop therapeutic kinase inhibitors, success has been limited. An alternative approach is to develop pharmaceuticals to enhance the activity of the principal phospho-tau phosphatase, phosphoprotein phosphatase 2A (PP2A). In this article we review evidence that this mechanism is pharmacologically achievable and has promise for delivering the next generation of Alzheimer's disease therapeutics. A number of different chemotypes have been reported to lead to enhanced PP2A activity through a range of proposed mechanisms. Some of these compounds appear to act directly as allosteric activators of PP2A, while others act indirectly by inhibiting the binding of PP2A inhibitors or by altering post-translational modifications that act in turn to regulate PP2A activity towards phospho-tau. These results indicate that PP2A may provide a useful target that can be safely, selectively and effectively modulated through pharmaceutical intervention to treat Alzheimer's disease.
Related Papers
- → α4 Is an Essential Regulator of PP2A Phosphatase Activity(2009)164 cited
- → DREADDs: novel tools for drug discovery and development(2013)93 cited
- → Regulation of Protein Phosphatase 2A Catalytic Activity by alpha4 Protein and Its Yeast Homolog Tap42(1998)114 cited
- → Structural genomics and drug discovery: all in the family(2008)43 cited
- → Pertussis Toxin Modification of PC12 Cells Inhibits a Protein Phosphatase 2A‐Like Phosphatase(1998)10 cited